Final outcome of patients treated with interferon alpha
| No (%) | |
|---|---|
| BD, Behçet’s disease, IFN, interferon; logMar, logarithm of the minimum angle of resolution; VA, visual acuity. | |
| *Significant difference between Behçet’s disease and non-Behçet’s disease groups. | |
| Uveitis associated with Behçet’s disease (n) | 23 |
| Long term IFN efficacy (n) | 19/23* (p = 0.07) |
| Follow-up (mo) (mean (range)) | 33.9 (18–59) |
| Mean initial VA (log MAR) | 0.45 (82.6) |
| Mean final VA (log MAR) | 0.3 |
| Stabilisation or improvement of VA (No of eyes) | 29/38 (76.3) |
| Mean initial steroid dose (mg/day) | 20.8 |
| Mean final steroid dose (mg/day) | 9.7 (p<0.001) |
| IFN discontinuation (n) | 10/19 (52.6) |
| Relapses after discontinuation (n) | 4/10 (40) |
| Non Behçet’s disease uveitis entities (n) | 22 |
| Long term IFN efficacy (n) | 13/22* (p = 0.07) (59) |
| Follow-up (mo) (mean (range)) | 22 (12–39) |
| Mean initial VA (log MAR) | 0.55 |
| Mean final VA (log MAR) | 0.4 |
| Stabilisation or improvement of VA (No of eyes) | 17/26 (65.4) |
| Mean initial steroid dose (mg/day) | 25.6 |
| Mean final steroid dose (mg/day) | 10.5 (p<0.001) |
| IFN discontinuation (n) | 4/13 (30.7) |
| Relapses after discontinuation (n) | 1/4 (25) |